Immune checkpoint inhibitor (ICI) combination therapy compared to monotherapy in advanced solid cancer: A systematic review

Ma, Xiaoting; Zhang, Yujian; Wang, Shan; Wei, Huamin; Yu, Jing

doi:10.7150/jca.49174

Cited by 34 publications

(31 citation statements)

References 36 publications

(19 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Indeed, TPS is used clinically as a predictive biomarker for response. 33 Third, patients receiving combined treatment (immunotherapy and chemotherapy) benefited more than anti-PD-1-based or anti-PD-L1-based monotherapy, as was previously shown, in some cases probably due to the chemotherapy 34 ( figure 1F ). Two mutations, KRAS and TP53 (measured in Cohort 2 only), correlated with response ( figure 1G, H ), though sample size was quite small.…”

Section: Resultsmentioning

confidence: 54%

Longitudinal plasma proteomic profiling of patients with non-small cell lung cancer undergoing immune checkpoint blockade

Harel¹,

Lahav²,

Jacob³

et al. 2022

J Immunother Cancer

View full text Add to dashboard Cite

BackgroundImmune checkpoint inhibitors (ICIs) have revolutionized the cancer therapy landscape due to long-term benefits in patients with advanced metastatic disease. However, robust predictive biomarkers for response are still lacking and treatment resistance is not fully understood.MethodsWe profiled approximately 800 pre-treatment and on-treatment plasma proteins from 143 ICI-treated patients with non-small cell lung cancer (NSCLC) using ELISA-based arrays. Different clinical parameters were collected from the patients including specific mutations, smoking habits, and body mass index, among others. Machine learning algorithms were used to identify a predictive signature for response. Bioinformatics tools were used for the identification of patient subtypes and analysis of differentially expressed proteins and pathways in each response group.ResultsWe identified a predictive signature for response to treatment comprizing two proteins (CXCL8 and CXCL10) and two clinical parameters (age and sex). Bioinformatic analysis of the proteomic profiles identified three distinct patient clusters that correlated with multiple parameters such as response, sex and TNM (tumors, nodes, and metastasis) staging. Patients who did not benefit from ICI therapy exhibited significantly higher plasma levels of several proteins on-treatment, and enrichment in neutrophil-related proteins.ConclusionsOur study reveals potential biomarkers in blood plasma for predicting response to ICI therapy in patients with NSCLC and sheds light on mechanisms underlying therapy resistance.

show abstract

Section: Resultsmentioning

confidence: 54%

Longitudinal plasma proteomic profiling of patients with non-small cell lung cancer undergoing immune checkpoint blockade

Harel¹,

Lahav²,

Jacob³

et al. 2022

J Immunother Cancer

View full text Add to dashboard Cite

show abstract

“…Combination immunotherapies such as chemotherapy combined with immune checkpoint inhibitor (ICI) therapy and ICI two-drug combination therapy are the current treatment trend. 42 LILRB4 expression has been shown to highly associated with CTLA-4 expression in chronic myelomonocytic leukemia (CMML) samples. 43 In this study, we observed that with the positive correlation between LILRB4 and PD-1, the combination therapy of anti-LILRB4/gp49B and anti-PD-1 mAbs showed higher anti-tumor metastasis ability compared to the monotherapy.…”

Section: Discussionmentioning

confidence: 99%

LILRB4 promotes tumor metastasis by regulating MDSCs and inhibiting miR-1 family miRNAs

Kumata

Endo

et al. 2022

OncoImmunology

View full text Add to dashboard Cite

“…We next analyzed the association between immune checkpoint inhibitors (ICIs) [ 29 ] and NXPH4. We found that NXPH4 was negatively associated with some ICIs such as CD40, CD200, LGALS9, and TNFRSF14 ( Figure 6(a,b )).…”

Section: Resultsmentioning

confidence: 99%

Neurexophilin 4 is a prognostic biomarker correlated with immune infiltration in bladder cancer

et al. 2022

View full text Add to dashboard Cite

Recent studies have shown that NXPH family member 4 (NXPH4) plays an important role in the progression of cancer. However, the potential role of NXPH4 in bladder cancer (BCa) remains to be explored. The purpose of the present study was to identify whether NXPH4 could be used as a biomarker to predict the prognosis of BCa. We first examined the expression of NXPH4 in pan-cancer, and then focused on BCa. Univariate and multivariate Cox regression analysis were used to investigate whether NXPH4 could be used as an independent prognostic indicator. Gene set enrichment analysis (GSEA) was used for functional analysis of NXPH4-related genes. CIBERSORT algorithm was used to calculate immune cell infiltration levels with different NXPH4 expression. Finally, the expression of NXPH4 was validated in clinical tissue specimens and bladder cancer cell lines by immunohistochemistry and qRT-PCR. The tumor-promoting effects of NXPH4 were further investigated using counting kit-8 (CCK-8), colony formation, EdU assays, and tumor xenograft model. Our results showed that NXPH4 was highly expressed in BCa tissues. Patients in the high NXPH4 expression group had shorter overall survival (OS) and progression-free survival (PFS). We found that immune-related pathways were enriched in NXPH4-related genes. Immune cell infiltrations in BCa were also associated with different NXPH4 expression. NXPH4 was further found to be highly expressed in our validation specimens. The proliferative effect of NXPH4 was confirmed in BCa in vivo and in vitro . Overall, NXPH4 is a biomarker for predicting BCa prognosis and associated with immune infiltration. Abbreviations: NXPH4: Neurexophilin 4; BCa: Bladder cancer; TCGA-BLCA: The Cancer Genome Atlas Urothelial Bladder Carcinoma; shRNA: short hairpin RNA; NC: Negative control; OS: Overall survival; PFS: Progression-free survival; TME: Tumor microenvironment; IPS: immunophenoscore; ICIs: Immune checkpoint inhibitors; DEGs: Differential expression genes.

show abstract

Immune checkpoint inhibitor (ICI) combination therapy compared to monotherapy in advanced solid cancer: A systematic review

Cited by 34 publications

References 36 publications

Longitudinal plasma proteomic profiling of patients with non-small cell lung cancer undergoing immune checkpoint blockade

Longitudinal plasma proteomic profiling of patients with non-small cell lung cancer undergoing immune checkpoint blockade

LILRB4 promotes tumor metastasis by regulating MDSCs and inhibiting miR-1 family miRNAs

Neurexophilin 4 is a prognostic biomarker correlated with immune infiltration in bladder cancer

Contact Info

Product

Resources

About